Engineered immune cells aim to stop smoldering myeloma in its tracks

This study tests a treatment called cilta-cel, which uses a patient's own immune cells (T cells) that are modified to attack myeloma cells. It is for people with high-risk smoldering myeloma, a condition that often leads to active multiple myeloma. The goal is to see if this one-time cell therapy is safe and can control the disease, potentially delaying or preventing its progression. About 20 participants will receive the treatment along with chemotherapy to prepare their bodies.